Calliditas Therapeutics
Rowland Elwell has extensive work experience in the medical affairs field. Rowland is currently working at Calliditas Therapeutics as the National Director of US Field Medical Affairs since August 2022. Prior to this role, they served as the Director of US Medical Affairs from May 2021 to August 2022.
Before joining Calliditas Therapeutics, Rowland worked at Regeneron for several years. Rowland'sroles at Regeneron included Director of Medical Affairs - Field, Immunology from January 2018 to May 2021, and Associate Director of Medical Affairs, Cardiovascular & Metabolism from June 2014 to December 2017.
Prior to their time at Regeneron, Rowland held a position as a Senior Regional Medical Liaison at Amgen from August 2005 to June 2014.
Rowland has also worked in academic settings. Rowland was an Assistant Professor of Pharmacy Practice at Albany College of Pharmacy from July 2003 to August 2005. Before that, they completed a Nephrology Fellowship at Albany College of Pharmacy from July 2001 to June 2003.
Rowland'sprofessional journey began as a Pharmacy Practice Resident at the Medical University of South Carolina from July 2000 to June 2001.
Rowland Elwell's education history includes earning a Bachelor of Science (BS) degree in Pharmacy from Albany College of Pharmacy and Health Sciences, which they attended from 1994 to 1999. Subsequently, they pursued a Doctor of Pharmacy (PharmD) degree from the same institution, completing their studies from 1998 to 2000.
This person is not in any teams
This person is not in any offices
Calliditas Therapeutics
2 followers
Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused onthe development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.